122 related articles for article (PubMed ID: 19759548)
1. Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation.
Jones CL; Wain EM; Chu CC; Tosi I; Foster R; McKenzie RC; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2010 Apr; 130(4):1116-25. PubMed ID: 19759548
[TBL] [Abstract][Full Text] [Related]
2. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation.
Wu J; Nihal M; Siddiqui J; Vonderheid EC; Wood GS
J Invest Dermatol; 2009 May; 129(5):1165-73. PubMed ID: 18923451
[TBL] [Abstract][Full Text] [Related]
3. Regulation of T-plastin expression by promoter hypomethylation in primary cutaneous T-cell lymphoma.
Jones CL; Ferreira S; McKenzie RC; Tosi I; Caesar JA; Bagot M; Whittaker SJ; Mitchell TJ
J Invest Dermatol; 2012 Aug; 132(8):2042-9. PubMed ID: 22495182
[TBL] [Abstract][Full Text] [Related]
4. Promoter-Specific Hypomethylation Is Associated with Overexpression of PLS3, GATA6, and TWIST1 in the Sezary Syndrome.
Wong HK; Gibson H; Hake T; Geyer S; Frederickson J; Marcucci G; Caligiuri MA; Porcu P; Mishra A
J Invest Dermatol; 2015 Aug; 135(8):2084-2092. PubMed ID: 25806852
[TBL] [Abstract][Full Text] [Related]
5. CD164 identifies CD4
Benoit BM; Jariwala N; O'Connor G; Oetjen LK; Whelan TM; Werth A; Troxel AB; Sicard H; Zhu L; Miller C; Takeshita J; McVicar DW; Kim BS; Rook AH; Wysocka M
Arch Dermatol Res; 2017 Jan; 309(1):11-19. PubMed ID: 27766406
[TBL] [Abstract][Full Text] [Related]
6. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas.
Ni X; Zhang C; Talpur R; Duvic M
J Invest Dermatol; 2005 Apr; 124(4):741-50. PubMed ID: 15816832
[TBL] [Abstract][Full Text] [Related]
7. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma.
Petak I; Danam RP; Tillman DM; Vernes R; Howell SR; Berczi L; Kopper L; Brent TP; Houghton JA
Cell Death Differ; 2003 Feb; 10(2):211-7. PubMed ID: 12700649
[TBL] [Abstract][Full Text] [Related]
8. EPHA4 is overexpressed but not functionally active in Sézary syndrome.
Hameetman L; van der Fits L; Zoutman WH; Out-Luiting JJ; Siegal G; de Esch IJ; Vermeer MH; Tensen CP
Oncotarget; 2015 Oct; 6(31):31868-76. PubMed ID: 26376612
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-181 contributes to downregulation of SAMHD1 expression in CD4+ T-cells derived from Sèzary syndrome patients.
Kohnken R; Kodigepalli KM; Mishra A; Porcu P; Wu L
Leuk Res; 2017 Jan; 52():58-66. PubMed ID: 27889686
[TBL] [Abstract][Full Text] [Related]
10. Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma.
Butler LM; Dobrovic A; Bianco T; Cowled PA
Br J Cancer; 2000 Jan; 82(1):131-5. PubMed ID: 10638979
[TBL] [Abstract][Full Text] [Related]
11. Epigenomic Analysis of Sézary Syndrome Defines Patterns of Aberrant DNA Methylation and Identifies Diagnostic Markers.
van Doorn R; Slieker RC; Boonk SE; Zoutman WH; Goeman JJ; Bagot M; Michel L; Tensen CP; Willemze R; Heijmans BT; Vermeer MH
J Invest Dermatol; 2016 Sep; 136(9):1876-1884. PubMed ID: 27113428
[TBL] [Abstract][Full Text] [Related]
12. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes.
Takahashi H; Feuerhake F; Kutok JL; Monti S; Dal Cin P; Neuberg D; Aster JC; Shipp MA
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3265-71. PubMed ID: 16740746
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of SATB1 expression in Sezary cells causes apoptosis resistance by regulating FasL/CD95L transcription.
Wang Y; Su M; Zhou LL; Tu P; Zhang X; Jiang X; Zhou Y
Blood; 2011 Apr; 117(14):3826-35. PubMed ID: 21270445
[TBL] [Abstract][Full Text] [Related]
14. RANKL regulates Fas expression and Fas-mediated apoptosis in osteoclasts.
Wu X; Pan G; McKenna MA; Zayzafoon M; Xiong WC; McDonald JM
J Bone Miner Res; 2005 Jan; 20(1):107-16. PubMed ID: 15619676
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA-21 expression in CD4+ T cells is regulated by STAT3 and is pathologically involved in Sézary syndrome.
van der Fits L; van Kester MS; Qin Y; Out-Luiting JJ; Smit F; Zoutman WH; Willemze R; Tensen CP; Vermeer MH
J Invest Dermatol; 2011 Mar; 131(3):762-8. PubMed ID: 21085192
[TBL] [Abstract][Full Text] [Related]
16. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
17. Global Patterns of Methylation in Sézary Syndrome Provide Insight into the Role of Epigenetics in Cutaneous T-Cell Lymphoma.
Whittaker S
J Invest Dermatol; 2016 Sep; 136(9):1753-1754. PubMed ID: 27542296
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of T-plastin in Sezary cells.
Su MW; Dorocicz I; Dragowska WH; Ho V; Li G; Voss N; Gascoyne R; Zhou Y
Cancer Res; 2003 Nov; 63(21):7122-7. PubMed ID: 14612505
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive analysis of PTEN status in Sezary syndrome.
Cristofoletti C; Picchio MC; Lazzeri C; Tocco V; Pagani E; Bresin A; Mancini B; Passarelli F; Facchiano A; Scala E; Lombardo GA; Cantonetti M; Caprini E; Russo G; Narducci MG
Blood; 2013 Nov; 122(20):3511-20. PubMed ID: 24062018
[TBL] [Abstract][Full Text] [Related]
20. FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.
Heid JB; Schmidt A; Oberle N; Goerdt S; Krammer PH; Suri-Payer E; Klemke CD
J Invest Dermatol; 2009 Dec; 129(12):2875-85. PubMed ID: 19626037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
